Loading
A phase 1/2 trial of Purinostat in multiple myeloma, run by Chengdu Zenitar Biomedical Technology Co., Ltd, now recruiting.
Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT06484829 by Chengdu Zenitar Biomedical Technology Co., Ltd, with 144 participants planned, started 2024-03-25 and due to reach its primary completion in 2026-02-01. Interventions recorded: Purinostat Mesylate 4 mg/m2, Purinostat Mesylate 6 mg/m2 and Purinostat Mesylate 8.4 mg/m2.
Shares Purinostat, Chengdu Zenitar Biomedical Technology and the tag pipeline.
Shares Purinostat, Chengdu Zenitar Biomedical Technology and the tag pipeline.
Shares Chengdu Zenitar Biomedical Technology and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.